Trial Profile
A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA or reference ESAs
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Methoxy polyethylene glycol-epoetin beta (Primary) ; Methoxy polyethylene glycol-epoetin beta (Primary) ; Darbepoetin alfa; Darbepoetin alfa; Epoetin alfa; Epoetin alfa; Epoetin beta; Epoetin beta
- Indications Anaemia
- Focus Adverse reactions
- Acronyms MIRCERA PASS; PASS
- Sponsors Roche
- 27 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 15 Feb 2018 New trial record